Oh, I did ask someone from invitro who had been with the company about 5 years whether they regretted selling the Bloomington facility. He said that it was too large for them and that their strategy changed after Bruce came aboard in that they no longer chose to engage in the relatively low margin manufacturing business. He seemed to feel there was plenty of room for manufacturing the reagents (and I suppose retinal tacks) at the Eden Prairie site. I'm not quite sure how to reconcile the new Eden Prairie building (which was described as being a couple of blocks away), with that assertion. Or the allusions to manufacturing various products for the Merck contract. I gather the new facility is sort of thought of as the base for the Merck funded Ivation efforts.
The various tentacles developing all over SRDX are fun and exciting, but I find myself wondering how they can be effectively managed. Relationships with just about everybody. Brookwood and SRDX people are striving to meet each others' customers as pairs. Necessary, but something someplace is going to be a problem.
Oh, I met the new head of business development. I remember thinking how much Phil was taking on his plate when he was given that responsibility along with his financial duties. Now it has been offloaded.
I hope there is something in here of value to you and that I've not inadvertantly revealed any proprietary information. This company still seems quite extraordinary to me.
Best, L.
AI
Market Data 
Markets 
